Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.
